Empagliflozin: a new strategy for nephroprotection in diabetes

Empagliflozin, an inhibitor of sodium–glucose symporter type 2 (SGLT2), is a new class of antidiabetic agents with numerous pleiotropic effects. The review summarises data on the influence of empagliflozin on the structural and functional changes in the kidneys of the models of diabetes me...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anton Ivanovich Korbut, Vadim Valer'evich Klimontov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2017
Materias:	diabetes diabetic nephropathy chronic kidney disease sglt2 inhibitors empagliflozin Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/13c2256433f64e878a433cb9f5179a47
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:13c2256433f64e878a433cb9f5179a47
record_format	dspace
spelling	oai:doaj.org-article:13c2256433f64e878a433cb9f5179a472021-11-14T09:00:21ZEmpagliflozin: a new strategy for nephroprotection in diabetes2072-03512072-037810.14341/DM8005https://doaj.org/article/13c2256433f64e878a433cb9f5179a472017-05-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/8005https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Empagliflozin, an inhibitor of sodium–glucose symporter type 2 (SGLT2), is a new class of antidiabetic agents with numerous pleiotropic effects. The review summarises data on the influence of empagliflozin on the structural and functional changes in the kidneys of the models of diabetes mellitus (DM) and of patients with DM. A literature search was conducted using the databases of Medline/PubMed, Scopus, Web of Science, ClinicalTrials.gov and eLibrary. The experimental results showed a decrease in the blood glucose level, blood pressure, glomerular hyperfiltration and overexpression of proinflammatory and fibrogenic factors in the kidneys under the influence of empagliflozin. Most clinical studies have demonstrated the albuminuria-lowering effect of empagliflozin in patients with type 2 DM. The EMPA-REG OUTCOME study has demonstrated slowing of the chronic kidney disease progression, decrease in the incidence of end-stage renal failure and death from renal causes in patients with type 2 DM undergoing the empagliflozin treatment compared with those receiving placebo. The mechanisms of the nephroprotective effect of empagliflozin included systemic and renal effects. The decrease in hyperglycaemia, blood pressure and body weight; reduction in glomerular hyperfiltration; enhancement of sodium excretion and suppression of inflammatory and fibrogenic signalling pathways in the kidneys may help slow the development of diabetic kidney damage under the influence of empagliflozin. The possibility of extrapolating the confirmed properties of empagliflozin to other SGLT2 inhibitors needs further investigation.Anton Ivanovich KorbutVadim Valer'evich KlimontovEndocrinology Research Centrearticlediabetesdiabetic nephropathychronic kidney diseasesglt2 inhibitorsempagliflozinNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 20, Iss 1, Pp 75-84 (2017)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes diabetic nephropathy chronic kidney disease sglt2 inhibitors empagliflozin Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes diabetic nephropathy chronic kidney disease sglt2 inhibitors empagliflozin Nutritional diseases. Deficiency diseases RC620-627 Anton Ivanovich Korbut Vadim Valer'evich Klimontov Empagliflozin: a new strategy for nephroprotection in diabetes
description	Empagliflozin, an inhibitor of sodium–glucose symporter type 2 (SGLT2), is a new class of antidiabetic agents with numerous pleiotropic effects. The review summarises data on the influence of empagliflozin on the structural and functional changes in the kidneys of the models of diabetes mellitus (DM) and of patients with DM. A literature search was conducted using the databases of Medline/PubMed, Scopus, Web of Science, ClinicalTrials.gov and eLibrary. The experimental results showed a decrease in the blood glucose level, blood pressure, glomerular hyperfiltration and overexpression of proinflammatory and fibrogenic factors in the kidneys under the influence of empagliflozin. Most clinical studies have demonstrated the albuminuria-lowering effect of empagliflozin in patients with type 2 DM. The EMPA-REG OUTCOME study has demonstrated slowing of the chronic kidney disease progression, decrease in the incidence of end-stage renal failure and death from renal causes in patients with type 2 DM undergoing the empagliflozin treatment compared with those receiving placebo. The mechanisms of the nephroprotective effect of empagliflozin included systemic and renal effects. The decrease in hyperglycaemia, blood pressure and body weight; reduction in glomerular hyperfiltration; enhancement of sodium excretion and suppression of inflammatory and fibrogenic signalling pathways in the kidneys may help slow the development of diabetic kidney damage under the influence of empagliflozin. The possibility of extrapolating the confirmed properties of empagliflozin to other SGLT2 inhibitors needs further investigation.
format	article
author	Anton Ivanovich Korbut Vadim Valer'evich Klimontov
author_facet	Anton Ivanovich Korbut Vadim Valer'evich Klimontov
author_sort	Anton Ivanovich Korbut
title	Empagliflozin: a new strategy for nephroprotection in diabetes
title_short	Empagliflozin: a new strategy for nephroprotection in diabetes
title_full	Empagliflozin: a new strategy for nephroprotection in diabetes
title_fullStr	Empagliflozin: a new strategy for nephroprotection in diabetes
title_full_unstemmed	Empagliflozin: a new strategy for nephroprotection in diabetes
title_sort	empagliflozin: a new strategy for nephroprotection in diabetes
publisher	Endocrinology Research Centre
publishDate	2017
url	https://doaj.org/article/13c2256433f64e878a433cb9f5179a47
work_keys_str_mv	AT antonivanovichkorbut empagliflozinanewstrategyfornephroprotectionindiabetes AT vadimvalerevichklimontov empagliflozinanewstrategyfornephroprotectionindiabetes
_version_	1718429510155632640

Empagliflozin: a new strategy for nephroprotection in diabetes

Ejemplares similares